Baiosaitu announced the merger of pythons and pharmaceuticals to create a globally influential source of innovative antibody drugs.

Introduction: On August 31, 2020, Biosaitu announced the merger of innovative biopharmaceutical research and development enterprises in the clinical phase - Yanhe Pharmaceuticals, Pharma and Pharmaceuticals will continue to operate as a wholly owned subsidiary of Biosaitu.
, Aug. 31, 2020 /A.T./ -- On August 31, 2020, Bai osaitu announced the merger of innovative biopharmaceutical research and development enterprises in the clinical phase - Yan and Pharmaceuticals, which will continue to operate as wholly-owned subsidiaries of Bai osaitu.
the merger was completed, Beo Saitu also transformed from CRO to Biotech.
As an international Biotech company, Biosaitu will form a complete new drug research and development system covering target verification, large-scale development of human antibody drugs, evaluation of drug effectiveness in different species of animals, IND declaration at home and abroad, and global clinical trials.
partners to create a more creative antibody drug development ecosystem and develop more innovative antibody drugs for the benefit of patients.
, Founder, Chairman and CEO of 100 Osaitu, said, "We are very pleased to have joined the Besaitu family with the pharmaceutical team.
and Pharmaceuticals have an internationally-available and experienced clinical development team, as well as a strong research and development pipeline.
less than four years after its establishment, three original antibody drugs have successfully advanced to the phase I clinical stage in Australia, while achieving drug development in cooperation with well-known domestic pharmaceutical companies, fully demonstrating the efficiency and execution of the pharmaceutical team.
" "Beyo Setu is committed to becoming one of the world's sources of innovative antibody drugs.
based on human antibody genetically modified mice RenMab and many genetically modified models of animal diseases, to create a unique high efficiency, high flute, high success rate of new drug research and development system.
with the implementation of the 'Million Rat Resistance' program, there is the ability to continuously contribute new drug targets and drug molecules validated by animal models of different species of primary disease.
has reached a consensus on cooperation and development of antibody drugs with nearly 10 new drug research and development enterprises at home and abroad on nearly 20 antibody targets, some of which have begun preclinical research and development.
clinical declaration and development capabilities of pharmaceuticals and pharmaceuticals complement the efficient preclinical new drug research and development system of Biosaitu.
With the start of construction of the company's antibody production and CMC base, Beo Saitu will form a full chain of research and development capabilities covering new drug research and development, as well as a team with extensive international industry experience in the field of early detection of biological drugs, preclinical research and clinical research.
With an open and cooperative business model and new drug research and development companies around the world, 100 Osaitu has worked closely together on all aspects of the process, from 'idea' to 'BLA', to accelerate the development of innovative antibody drugs.
"